Serious side effects, including neurotoxicity and intestinal inflammation, that appear weeks or months after patients receive ...

T cell therapy anitocabtagene autoleucel (anito-cel) continued to show strong results in treating relapsed/refractory ...

Research presented December 8 at the American Society of Hematology Conference in Florida, has shown that a new kind of CAR T ...

March Bio is continuing enrollment in the Phase 2 trial, with the Independent Data Monitoring Committee's approval to advance to Simon Stage 2 of the Phase 2 trial. The Company anticipates presenting ...

Chimeric antigen receptor (CAR) T-cell therapy can cure certain types of blood cancer, but cost and a general lack of ...

Cancer Research UK's Centre for Drug Development is sponsoring and conducting the phase I/II clinical trial of ALETA-001, the lead agent in Aleta Biotherapeutics' portfolio. Additional clinical trial ...

A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may ...

A cutting-edge base-edited CAR T-cell therapy is opening a revolutionary new frontier for patients battling aggressive T-cell leukemia.

New three-year follow-up results from the TRANSCEND FL trial show that patients with relapsed or refractory follicular ...

Discover the nuances of CAR T-cell therapy eligibility and its advantages over traditional chemotherapy for long-term patient ...

Measuring the lymphocytes - white blood cells that fight infection - in a patient's blood can be used to predict outcomes in ...

The global CAR T-Cell Therapy for Multiple Myeloma market is experiencing transformative growth, driven by advances in BCMA-targeted therapies like FDA-approved Abecma and Carvykti. These treatments ...